chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chills, Pain
Clinical narrative: Cold chills; Body ache especially button; Lower back pain; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 12:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 17Mar2021 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. The patient did not receive other vaccine within four weeks prior to the vaccination. On 22Apr2021 at 00:00 the patient experienced cold chills, body ache especially button and lower back pain. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event cold chills, body ache especially button and lower back pain was unknown at the time of reporting.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Complex regional pain syndrome, Condition aggravated
Clinical narrative: RSD/ CRPS flared up, normal symptoms of that disorder.; RSD/ CRPS flared up; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in left arm on 30Mar2021 at 16:15 (at the age of 22-years old) as a single dose for COVID-19 immunisation. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in left arm on 20Apr2021 at 16:15 (at the age of 22-years old) as a single dose for COVID-19 immunisation. The patient's medical history included reflex sympathetic dystrophy/ chronic regional pain syndrome. Known allergies were not reported   The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Apr2021 at 16:00, approximately 24 hours after each dose the patient had experienced reflex sympathetic dystrophy/ chronic regional pain syndrome flared up .  The events did not result in doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of adverse events. The clinical outcome of the event, reflex sympathetic dystrophy/ chronic regional pain syndrome flared up was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Have had tinnitus in both ears for most of life; the second day after second dose of COVID vaccine and for many days after and now periodically, my tinnitus is noticeably much worse. with flare ups occurring; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the right arm on 26Mar2021 at 12:45 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included tinnitus, allergy to latex, lanolin and nickel. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram (reported as generic LEXAPRO) and paracetamol (TYLENOL); both from unknown date for unknown indication and unknown if ongoing. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 05Mar2021 at 12:30 (at the age of 52-year-old) as a single dose for COVID-19 immunisation and took moxifloxacin hydrochloride (AVELOX), erythromycin (MANUFACTURER UNKNOWN), brompheniramine maleate; pseudoephedrine hydrochloride (BROMFED) and cefdinir (OMNICEF); all on unknown date for unknown indication and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient has had tinnitus in both ears for most of life, on 27Mar2021, the second day after second dose of COVID vaccine and for many days after and now periodically, the patient's tinnitus was noticeably much worse. Currently, it seemed to be levelling off at a new, higher volume level than prior to the second dose with flare ups occurring more often. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus worse was resolved with sequelae on unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Typical aura without headache, Vision blurred, Visual field defect
Clinical narrative: Blurring of vision; Posssibly silent migraine; Blind spot in vision; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 20Apr2021 at 17:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 30Mar2021 at 05:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 08:00, the patient experienced blurring of vision, blind spot in vision and possibly silent migraine. The events resulted in doctor or other healthcare professional office or clinic visit. Since the vaccination, the patient had not been tested for COVID-19. It was unknown whether therapeutic measures were taken as a result of the reported events. The clinical outcome of the events blurring of vision, blind spot in vision and possibly silent migraine were unknown at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Vertigo which I am still experiencing almost 3 weeks after first dose.; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 05Apr2021 at 15:15 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021, the patient had vertigo and was still experiencing at the time of reporting almost 3 weeks after the first dose. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event vertigo and was still experiencing almost 3 weeks after first dose was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Strong vertigo. cant even stand or leave the bed because of it.; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 (at the age of 33-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was not aware if she had any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included ethinylestradiol/drospirenone (YASMIN) as birth control pills from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 22Apr2021at 09:45, 5 days after vaccination, the patient experienced strong vertigo. The patient was not able to stand or leave the bed because of it. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the event strong vertigo was not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Pain
Clinical narrative: 12 hours post injection patient experienced body aches; Chills lasting around 24 hours; This is a spontaneous report from a contactable consumer. A 52-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 19Apr2021 at 10:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and eggs allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications within two weeks prior to the vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 29Mar2021 at 12:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 19Apr2021 at 22:00, 12 hours post vaccination, the patient experienced body aches and chills lasting around 24 hours. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events body aches and chills lasting was recovered on 20Apr2021 after a duration of 24 hours.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Depression, Muscle spasms, Ovulation disorder
Clinical narrative: Ovulation cycle 1.5 weeks early, 1 week after vaccine; Unusually strong cramping; and depression during ovulation; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EL9265) via an unspecified route of administration in the left arm on 08Apr2021 at 16:00 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. Medical history included polycystic ovarian syndrome (PCOS). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient had no known allergies. On an unknown date in Apr2021, one week after vaccine the patient ovulation cycle was 1.5 weeks early, the patient experienced unusually strong cramping and depression during ovulation. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events ovulation cycle 1.5 weeks early, unusually strong cramping and depression during ovulation were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Burning/stinging at shot site; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the arm left on 08Apr2021 at 15:30 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history included possible peripheral neuropathy, dairy allergy and iodine allergy. Concomitant medications included vitamin b complex (B COMPLEX), ascorbic acid (VITAMIN C), magnesium (MANUFACTURER UNKNOWN) and acetylcysteine (MANUFACTURER UNKNOWN), probiotics (MANUFACTURER UNKNOWN) and Omeg- (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 00:00, the patient experienced burning/stinging at shot site. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event burning/stinging at shot site was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Hypoaesthesia, Pain in jaw, Paraesthesia
Clinical narrative: Immediately after the vaccine I had a metallic taste in my mouth that went away.; After 20 minutes it felt like I had just received a novocaine injection in the left side of my jaw. It's sore and feels like very mild numbness and tingling.; After 20 minutes it felt like I had just received a novocaine injection in the left side of my jaw. It's sore and feels like very mild numbness and tingling.; After 20 minutes it felt like I had just received a novocaine injection in the left side of my jaw. It's sore and feels like very mild numbness and tingling.; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 22Apr2021 at 10:15 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and obesity. The patient had no known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination included levothyroxine (MANUFACTURER UNKNOWN), vitamin d nos (MANUFACTURER UNKNOWN), omeprazole (PRILOSEC) and ubidecarenone (COQ10); all from unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 25Mar2021 at 12:45 (at the age of 38-years-old) as a single dose for COVID-19immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 10:45, immediately after the vaccine, the patient had a metallic taste in her mouth that went away. After 20 minutes it felt like she had just received a novocaine injection in the left side of her jaw. It was sore and felt like very mild numbness and tingling. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event had a metallic taste in her mouth that went away was resolved on 22Apr2021, while that of after 20 minutes it felt like she had just received a novocaine injection in the left side of her jaw; it was sore and felt like very mild numbness and tingling was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Hot flush, Hyperhidrosis, Nausea
Clinical narrative: Sweat profusely; Hot flashes; Chills; Nausea; General fatigue; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ewo151) via an unspecified route of administration in the right arm on 02Apr2021 at 10:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high, contrast media allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) 20 mg and escitalopram oxalate (LEXAPRO) 20 mg all from an unknown date for an unspecified indication. On 02Apr2021 at 15:00, the patient experienced sweat profusely, had hot flashes, chills, nausea, general fatigue and body aches. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with prescription for anti-nausea, and liposomal glu. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sweat profusely, had hot flashes, chills, nausea, general fatigue and body aches was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Sweat profusely; Hot flashes; Chills; Nausea; General fatigue; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ewo151) via an unspecified route of administration in the right arm on 02Apr2021 at 10:30 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high, contrast media allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) 20 mg and escitalopram oxalate (LEXAPRO) 20 mg all from an unknown date for an unspecified indication. On 02Apr2021 at 15:00, the patient experienced sweat profusely, had hot flashes, chills, nausea, general fatigue and body aches. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with prescription for anti-nausea, and liposomal glu. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sweat profusely, had hot flashes, chills, nausea, general fatigue and body aches was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chills, Fatigue, Headache, Lymph node pain
Clinical narrative: Fatigue; Pain/redness/lump at injection site,; Pain/redness/lump at injection site; Pain/redness/lump at injection site; Swollen/painful lymph nodes under right arm; Swollen/painful lymph nodes under right arm; Runny nose; Chills; Headache; Back ache; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 02Apr2021 at 12:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), carvedilol (MANUFACTURER UNKNOWN), doxazosin (MANUFACTURER UNKNOWN) and atorvastatin (MANUFACTURER UNKNOWN); all started on unknown dates and for unspecified indications. The Patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 05Mar2021 at 12:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. On 03Apr2021, the patient experienced fatigue, pain/redness/lump at injection site, swollen/painful lymph nodes under right arm, runny nose, chills, headache and back ache. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events fatigue, pain/redness/lump at injection site, swollen/painful lymph nodes under right arm, runny nose, chills, headache and back ache was recovering at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Rhinorrhoea, Vaccination site erythema, Vaccination site mass, Vaccination site pain
Clinical narrative: Fatigue; Pain/redness/lump at injection site,; Pain/redness/lump at injection site; Pain/redness/lump at injection site; Swollen/painful lymph nodes under right arm; Swollen/painful lymph nodes under right arm; Runny nose; Chills; Headache; Back ache; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 02Apr2021 at 12:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), carvedilol (MANUFACTURER UNKNOWN), doxazosin (MANUFACTURER UNKNOWN) and atorvastatin (MANUFACTURER UNKNOWN); all started on unknown dates and for unspecified indications. The Patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 05Mar2021 at 12:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. On 03Apr2021, the patient experienced fatigue, pain/redness/lump at injection site, swollen/painful lymph nodes under right arm, runny nose, chills, headache and back ache. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events fatigue, pain/redness/lump at injection site, swollen/painful lymph nodes under right arm, runny nose, chills, headache and back ache was recovering at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Body temperature, Dizziness, Epistaxis, Fatigue
Clinical narrative: Migraine; Dizziness; Multiple bloody noses throughout the day; Started feeling flu symptoms; Tired; Weak; Body ache; Fever of 101; fever went went up to 103.5 on 17Apr2021; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration on 13Apr2021 (at the age of 35-years-old); as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 16Apr2021, the patient started feeling flu symptoms, tired, weak, body aches and fever of 101. On 17Apr2021, fever went up to 103.5 and patient started having migraines, dizziness and multiple bloody noses throughout the day.  Fever came and went until 19Apr2021 (at the time of report), but was still experiencing bloody noses, body ache and migraines.  Since the vaccination, the patient had been tested for COVID-19. The patient underwent lab tests and procedures which included COVID-19 virus test on 18Apr2021 and the results were pending. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events started feeling flu symptoms, tired, weak, body ache, multiple bloody noses, dizziness and migraine were not recovered at the time of this report. The clinical outcome of fever of 101, fever went up to 103.5 was recovered on 19Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza, Migraine, Pain, Pyrexia, SARS-CoV-2 test
Clinical narrative: Migraine; Dizziness; Multiple bloody noses throughout the day; Started feeling flu symptoms; Tired; Weak; Body ache; Fever of 101; fever went went up to 103.5 on 17Apr2021; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration on 13Apr2021 (at the age of 35-years-old); as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 16Apr2021, the patient started feeling flu symptoms, tired, weak, body aches and fever of 101. On 17Apr2021, fever went up to 103.5 and patient started having migraines, dizziness and multiple bloody noses throughout the day.  Fever came and went until 19Apr2021 (at the time of report), but was still experiencing bloody noses, body ache and migraines.  Since the vaccination, the patient had been tested for COVID-19. The patient underwent lab tests and procedures which included COVID-19 virus test on 18Apr2021 and the results were pending. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events started feeling flu symptoms, tired, weak, body ache, multiple bloody noses, dizziness and migraine were not recovered at the time of this report. The clinical outcome of fever of 101, fever went up to 103.5 was recovered on 19Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling hot, Mass, SARS-CoV-2 test
Clinical narrative: Large bump; Large bump hot to touch; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 16Apr2021 at 11:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) on an unknown date and for unspecified indication and experienced drug allergy. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Mar2021 at 12:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. On 09Apr2021, the patient underwent for COVID-19 virus test (nasal swab) and the results were found to be negative. On 17Apr2021 the patient experienced the event large bump hot to touch. Since the vaccination, the patient had been tested for COVID-19. No therapeutic measures were taken as the result of the reported events. The clinical outcome of the event large bump hot to touch was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Pain, Pain in extremity, Rash erythematous
Clinical narrative: The site is painful and itchy.; The site is painful and itchy.; Red rash; Arm has been very sore; Headache; Body aches; Nausea; Large baseball size swelling at incision site the night after vaccination; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included multi-vitamin (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 02Apr2021 at 10:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. On 21Apr2021, the patient experienced large baseball size swelling at incision site the night after vaccination. On 21Apr2021 at 12:00, the site was painful and itchy. The patient developed red rash. The patient's arm had been very sore and all other side effects had been present like headache, body aches and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the events large baseball size swelling at incision site, site was painful, itchy and red rash which included treatment with diphenhydramine hydrochloride (BENADRYL) and anti-itch cream (Unspecified). Therapeutic measures were not taken as a result of the events arm has been very sore, headache, body aches and nausea. The clinical outcome of the events large baseball size swelling at incision site the night after vaccination, site was painful, itchy, red rash, arm has been very sore, headache, body aches and nausea were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: The site is painful and itchy.; The site is painful and itchy.; Red rash; Arm has been very sore; Headache; Body aches; Nausea; Large baseball size swelling at incision site the night after vaccination; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included multi-vitamin (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 02Apr2021 at 10:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. On 21Apr2021, the patient experienced large baseball size swelling at incision site the night after vaccination. On 21Apr2021 at 12:00, the site was painful and itchy. The patient developed red rash. The patient's arm had been very sore and all other side effects had been present like headache, body aches and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the events large baseball size swelling at incision site, site was painful, itchy and red rash which included treatment with diphenhydramine hydrochloride (BENADRYL) and anti-itch cream (Unspecified). Therapeutic measures were not taken as a result of the events arm has been very sore, headache, body aches and nausea. The clinical outcome of the events large baseball size swelling at incision site the night after vaccination, site was painful, itchy, red rash, arm has been very sore, headache, body aches and nausea were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Pain in left arm; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 14:30 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. On 22Apr2021, the patient experienced pain in left arm. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pain in left arm was resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle tightness, Trismus
Clinical narrative: Muscles in neck close to jaw tight after event.; Chewing makes jaw lock.; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 13:30 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history included pre-diabetic, allergy, seasonal allergy, and cramps. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included diphenhydramine, paracetamol, phenylpropanolamine hydrochloride (BENADRYL) for allergy and ibuprofen sodium (IBUPROFEN) for cramps. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Mar2021 at 14:45 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. On 20Apr2021 at 06:00 the patient had mouth locked up and could not move jaw for a minute or so. Chewing made jaw lock. The patient could only chew in tiny bites. It started 2nd day after shot and muscles in jaw tight. Muscles in neck close to jaw tight after event. Symptom did not seem to be improving. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events muscle tightness and lock jaw were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Balance disorder, Chills, Dizziness, Fatigue
Clinical narrative: Chills; Vomiting at about 5 times thru the night; Very tired; Night sweats; Dizzy; Very weak; Balance; This is a spontaneous report from a contactable consumer, the patient. A 79-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 11:00 (at the age of 79-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 and sulpha allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included simvastatin (MANUFACTURER UNKNOWN) for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 18:00 (at the age of 79-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 19:00, the patient experienced chills for about an hour, vomiting 5 times through the night, very tired, night sweats, very weak, dizzy and balance. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event chills, vomiting, very tired, night sweats, very weak, dizzy and balance was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Night sweats, Vomiting
Clinical narrative: Chills; Vomiting at about 5 times thru the night; Very tired; Night sweats; Dizzy; Very weak; Balance; This is a spontaneous report from a contactable consumer, the patient. A 79-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 11:00 (at the age of 79-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 and sulpha allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included simvastatin (MANUFACTURER UNKNOWN) for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 18:00 (at the age of 79-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 19:00, the patient experienced chills for about an hour, vomiting 5 times through the night, very tired, night sweats, very weak, dizzy and balance. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event chills, vomiting, very tired, night sweats, very weak, dizzy and balance was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: U
Vaccine: COVID19
Symptoms: Chills, Myalgia, Nausea, Paraesthesia, Pyrexia
Clinical narrative: Muscle soreness; Tingling in right arm; Low grade fever; Chills; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the right arm on 18Apr2021 at 12:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy (PCN allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not received any concomitant medication within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the arm left on 26Mar2021 at 12:15 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 the patient experienced muscle soreness, tingling in right arm, low grade fever, chills and nausea. Therapeutic measures were taken as a result of muscle soreness, tingling in right arm, low grade fever, chills, and nausea and included treatment with Tylenol and Advil from unknown date. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event muscle soreness, tingling in right arm, low grade fever, chills, and nausea was recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Vomiting
Clinical narrative: Nausea; Vomiting; Headache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in left arm on 18Apr2021 at 16:15 (at the age of 16-years old), as a single dose for COVID-19 immunisation. Medical history included allergy to shellfish. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 19Apr2021, the patient had experienced nausea, vomiting, headache and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of events nausea, vomiting, headache and fatigue and which included treatment with acetaminophen. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events, nausea, vomiting, headache and fatigue was recovering at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: Nausea began 3-4 days after injection.I've had nausea for more than a week now.; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 09Apr2021 at 18:30 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to black olives. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included paracetamol (MANUFACTURER UNKNOWN). for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 13Apr2021 at 14:00, the patient experienced nausea which began 3-4 days after injection, and the patient had nausea for more than a week now. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination the patient not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event nausea was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.